Otvechaya potrebnostyam podrostkov. V trende - prolongirovannaya kontratseptsiya, v fokuse - kachestvo konsul'tirovaniya


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

This review summarizes modern contraceptive strategy for adolsent girls, based on wider application of methods of prolonged reversible contraception. The safety of intrauterine contraceptive devices in this age group and the need for protection from sexually transmitted infections are discussed.

全文:

受限制的访问

作者简介

T. Bebneva

Email: bebn@mail.ru

G. Dikke

Email: galadikke@yandex.ru

参考

  1. Medical eligibility criteria for contraceptive use. 4th ed. Switzerland: WHO, 2010.
  2. American College of Obstetricians and Gynecologists. Long-acting reversible contraception: implants and intrauterine devices. Guideline Summary. 2011. NGC: 008627.
  3. Основные показатели здоровья матери и ребенка, деятельность службы охраны детства и родовспоможения в Российской Федерации. М., 2012.
  4. Дикке Г.Б., Ерофеева Л.В. Особенности репродуктивного поведения молодежи. Акушерство и гинекология. 2013; 12: 96-101.
  5. Уварова Е.В. Комбинированная гормональная к контрацепция у сексуально- активных подростков и молодежи. РМЖ. 2008; 19: 1232.
  6. Thompson K.M., Speidel J.J., Saporta V., et al. Contraception. 2011; 83(1): 41-7.
  7. Abma J.C., Martinez G.M., Copen C.E. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, National Survey of Family Growth 2006-2008. National Center for Health Statistics. Vital Health Stat. 2010; (30): 1-47.
  8. Peipert J.F., Zhao Q., Allsworth J.E., et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011; 117(5): 1105-13. doi: 10.109 7/AOG.0b013e31821188ad
  9. Long-Acting Reversible Contraception in the Context of Full Access, Full Choice 18 December 2013. Press Releases. Share: 2013 Statement from the Bellagio Group on LARCs. Электронный ресурс. Режим доступа: http://www.popcouncil.org
  10. Медицинские критерии приемлемости методов контрацепции РФ. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ», 4-е изд., 2009. М., 2012. 241 с.
  11. Faculty of Sexual and Reproductive Healthcare - Professional Association. Progestogen-only implants. Guideline Summary. 2008; NGC: 006465.
  12. Selected practice recommendations for contraceptive use - 2nd ed., World Health Organization, 2005.
  13. Grimes D.A., Lopez L.M., Schulz K.F., Stanwood N.L. Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst. Rev. 2010; (6): CD001777.
  14. Heikinheimo O., Gissler M., Suhonen S. Age, parity, history of abortion and contraceptive choices affect the risk of repeat abortion. Contraception 2008; 78: 149-54.
  15. Finer L.B., Zolna M.R. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception. 2011; 84: 478-85.
  16. Finer L.B., Jerman J., Kavanaugh M.C. Changes in use of long-acting contraceptive methods in the United States, 2007-2009. Fertil. Steril. 2012. doi: 10.1016/j.fertnstert. 2012.06.027.
  17. Raine T.R., Foster-Rosales A., Upadhyay U.D., et al. One-year contraceptive continuation and pregnancy in adolescent girls and women initiating hormonal contraceptives. Obstet. Gynecol. 2011; 117: 363-71.
  18. Winner B., Peipert J.F., Zhao Q., et al. Effectiveness of long-acting reversible contraception. N. Engl. J. Med. 2012; 366: 1998-2007.
  19. Fleming K.L., Sokoloff A., Raine T.R. Attitudes and beliefs about the intrauterine device among teenagers and young women. Contraception. 2010; 82: 178-82.
  20. Lyus R., Lohr P., Prager S. Use of the Mirena LNGIUS and Paragard CuT380A intrauterine devices in nulliparous women. Board of the Society of Family Planning. Contraception. 2010; 81: 367-71.
  21. Hov G.G., Skjeldestad F.E., Hilstad T. Use of IUD and subsequent fertility-follow-up after participation in a randomized clinical trial. Contraception. 2007; 75: 88-92.
  22. Кротин П.Н., Кожуховская Т.Ю., Таенкова А.А. Репродуктивное поведение и контрацептивный выбор подростков и молодежи. РМЖ. 2004; 5: 341-46.
  23. Тихомирова Н.И., Швецов С.Э., Олейникова О.Н. и др. Внутриматочный контрацептив ведущий фактор в этиологии воспалительных заболеваний органов малого таза. Нижегородский медицинский журнал. 1999; 3: 30-2.
  24. Коколина В.Ф. Подростковая контрацепция. Практика педиатра. 2008; 10: 12-6.
  25. Серов В.Н. Репродуктивное поведение и здоровье женщины / Материалы II нац. ассамблеи. М., 1997. С.43-5.
  26. Suhonen S., Haukkamaa M., Jakobsson T., Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception. 2004; 69: 407-12.
  27. Карахалис Л.Ю. Выбор метода контрацепции в возрасте пременопаузы / Материалы IV Российского форума «Мать и дитя». Ч. 2. М., 2002. С. 175-76.
  28. Кира Е.Ф. Бактериальный валжоз. СПб., 2001. 363 с. 40.
  29. Arias R.D. Compelling reasons for recommending IUDs to any woman of reproductive age. Int. J. Fertil. Womens Med. 2002; 47(2): 87-95.
  30. Hubacher D., Lara-Ricalde R., Taylor D.J., Guerra-Infante F., Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N. Engl. J. Med. 2001; 345: 561-67.
  31. Thonneau P., Almont T., de La Rochebrochard E., Maria B. Risk factors for IUD failure: results of a large multicentre case-control study. Hum. Reprod. 2006; 21: 2612-16.
  32. Steenland M.W., Tepper N.K., Curtis K.M., Kapp N. I ntrauterine contraceptive insertion postabortion: a systematic review. Contraception. 2011; 84(5): 447-64.
  33. Mohllajee A.P., Curtis K.M., Peterson H.B. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception. 2006; 73: 145-53.
  34. Faundes A., Telles E., Cristofoletti M.L., et al. The risk of inadvertent intrauterine device insertion in women carriers of endocervical Chlamydia trachomatis. Contraception. 1998; 58: 105-09.
  35. Deans E.I., Grimes D.A. Intrauterine devices for adolescents: a systematic review. Contraception. 2009; 79: 418-23.
  36. Schreiber C.A., Sober S., Ratcliffe S., Creinin M. Ovulation resumption after medical abortion with mifepristone and misoprostol. Contraception. 2011; 84: 230-33.
  37. Boesen H.C., Rorbye C., Norgaard M., Nilas L. Sexual behavior during the first eight weeks after legal termination of pregnancy. Acta Obstet. Gynecol. Scand. 2004; 83: 1189-92.
  38. Long-acting reversible contraception the effective and appropriate use of long-acting reversible contraception. National Collaborating Centre for Women's and Children's Health. RCOG, 2013.
  39. Saav I., Stephansson O., Gemzell-Danielsson K. Early versus Delayed Insertion of Intrauterine Contraception after Medical Abortion - A Randomized Controlled Trial. 2012. Clin. Trials. gov NCT0153756.
  40. Shimoni N., Davis A., Ramos M., et al. Timing of Copper Intrauterine Device Insertion After Medical Abortion: A Randomized Controlled Trial. Obst. Gyn. 2011; 118(3): 623-28.
  41. Halpern V., Grimes D.A., Lopez L., Gallo M.F. Strategies to improve adherence and acceptability of hormonal methods for contraception. Cochrane Database Syst. Rev. 2007; Issue 4: CD004317.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2014
##common.cookie##